Medtronic Reports Strong FY26 Revenue Growth, Faces $1.1B Antitrust Verdict
Summary
Medtronic plc reported an 8% increase in net sales and higher EPS for fiscal year 2026, but faces a significant $1.1 billion trebled jury verdict in an antitrust lawsuit, which it plans to appeal.
Key Events
-
Strong Fiscal Year 2026 Financials
Net sales increased 8% to $36.364 billion, GAAP diluted EPS rose to $3.73, and operating cash flow reached $7.330 billion for the fiscal year ended April 24, 2026.
-
Major Antitrust Verdict Against Company
A jury returned a verdict against Medtronic for $382 million in an antitrust lawsuit brought by Applied Medical, which will be automatically trebled to approximately $1.146 billion. Medtronic believes the verdict is inconsistent with law and evidence and plans to challenge it.
-
Strategic Diabetes Business Separation Progresses
The MiniMed Group, Inc. initial public offering (IPO) was completed on March 9, 2026, with Medtronic retaining a 90.03% ownership interest. The company plans to complete the full separation of its Diabetes Business within the next fiscal year.
-
Key Acquisitions Expand Portfolios
Medtronic completed the $525 million acquisition of CathWorks Ltd. in April 2026 and announced the pending $650 million acquisition of SPR Therapeutics, Inc. in May 2026, expanding its Cardiovascular and Neuroscience portfolios.
Analysis
Medtronic's annual report highlights a year of solid financial growth, with robust revenue and EPS increases, demonstrating operational strength. The strategic move to separate the Diabetes business via the MiniMed IPO and several key acquisitions signal a focused effort on portfolio optimization and expansion in core areas. However, the significant jury verdict in the Applied Medical antitrust lawsuit, potentially totaling over $1.1 billion after trebling, introduces a substantial contingent liability and a major legal challenge that could materially impact future financial results, despite the company's intent to appeal. The disclosure of a cybersecurity incident, while currently deemed non-material, adds a layer of operational risk to monitor.
At the time of this filing, MDT was trading at $79.81 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $101.9B. The 52-week trading range was $73.31 to $106.33. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.